Patents by Inventor Michael F Good
Michael F Good has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12383630Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.Type: GrantFiled: May 24, 2023Date of Patent: August 12, 2025Assignee: GRIFFITH UNIVERSITYInventors: Michael F. Good, Manisha Pandey, Michael Raymond Batzloff
-
Publication number: 20230382981Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.Type: ApplicationFiled: May 24, 2023Publication date: November 30, 2023Applicant: GRIFFITH UNIVERSITYInventors: Michael F. GOOD, Manisha PANDEY, Michael Raymond BATZLOFF
-
Patent number: 11732033Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.Type: GrantFiled: August 22, 2018Date of Patent: August 22, 2023Assignee: GRIFFITH UNIVERSITYInventors: Michael F. Good, Manisha Pandey, Michael Raymond Batzloff
-
Publication number: 20210024619Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.Type: ApplicationFiled: August 22, 2018Publication date: January 28, 2021Applicant: GRIFFITH UNIVERSITYInventors: Michael F. GOOD, Manisha PANDEY, Michael Raymond BATZLOFF
-
Publication number: 20110064745Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.Type: ApplicationFiled: August 23, 2010Publication date: March 17, 2011Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
-
Publication number: 20090162369Abstract: The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling immunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protecting antibodies against Group A streptococci.Type: ApplicationFiled: December 11, 2008Publication date: June 25, 2009Inventors: Katin Helena Threse Nordstrom, Michael F. Good, Michael R. Batzloff
-
Publication number: 20090010929Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.Type: ApplicationFiled: December 4, 2007Publication date: January 8, 2009Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
-
Publication number: 20080175868Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: ApplicationFiled: July 24, 2007Publication date: July 24, 2008Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H. Lowell, George L. White, Michael Raymond Batzloff, David S. Burt, Tomas B. Leanderson, Michael F. Good
-
Patent number: 7255867Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: GrantFiled: November 13, 2003Date of Patent: August 14, 2007Assignees: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
-
Publication number: 20020169264Abstract: The present invention provides polymers incorporating peptides. The polymers comprise polymarised units of (1) CH2═CR4—CO—X—R1 and (2) CH2═CR3—CO—R2 and optionally one or more other monomers, in which R1 is a peptide. Each R1 may be the same, or is preferably different. In another embodiment the present invention provides polymers formed from CH2═CR4—CO—X—R1 and optionally one or more other monomers, in which X is a spacer having a length equivalent to 1 to 30 single C—C bonds and R1 is a peptide, each R1 being the same or different. The invention further relates to methods producing the polymers and methods of inducing an immune response using the polmers.Type: ApplicationFiled: January 11, 2002Publication date: November 14, 2002Applicant: The Council of the Queensland Institute of Medical ResearchInventors: David C. Jackson, Neil M. O'Brien-Simpson, Lorena E. Brown, Nicholas J. Ede, Evelyn R. Brandt, Michael F. Good, Weiguang Zeng
-
Patent number: 5028425Abstract: A purified peptide which induces proliferation or activation of cytotoxic T cells specifically against circumsporozoite protein of P. falciparum is described. The peptide has an amino acid sequence KPKDELDYENDIEKKICKMEKCS in single letter amino acid code.Type: GrantFiled: July 7, 1988Date of Patent: July 2, 1991Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael F. Good, Sanjai Kumar, Jay A. Berzofsky, Louis H. Miller